Should grade 3 endometrioid endometrial carcinoma be considered a type 2 cancer-A clinical and pathological evaluation.

Martin Voss; Raji Ganesan; L Ludeman; K McCarthy; R Gornall; G Schaller; Wenbin Wei; Sudha Sundar

doi:10.1016/j.ygyno.2011.07.030

Should grade 3 endometrioid endometrial carcinoma be considered a type 2 cancer-A clinical and pathological evaluation.

Martin Voss, Raji Ganesan, L Ludeman, K McCarthy, R Gornall, G Schaller, Wenbin Wei, Sudha Sundar

Cancer and Genomic Sciences

Research output: Contribution to journal › Article › peer-review

110 Citations (Scopus)

Abstract

OBJECTIVE: Endometrial cancer is classified into: Type I estrogen-dependent endometrioid adenocarcinoma, with good prognosis and type 2 non-estrogen-dependent cancer with serous or clear cell histology and poor prognosis. Grade 3 endometrioid cancers (G3 EEC), share features of type 1 and type 2 cancer and have not been classified as either. This study compares immunohistochemistry and survival in G3 EEC and type 2 cancers. METHODS: Clinicopathological data compared with immunohistochemistry and survival in 156 consecutive patients with poor prognosis cancer-G3 EEC, uterine papillary serous (UPSC) and clear cell carcinoma (CC), sarcoma, carcinosarcoma and endometrial tumors of mixed histology. 131 (84%) datasets were complete, 25 tumors comprising sarcoma, carcinosarcoma or mixed histologies were excluded. Tissue microarray constructed and tested for estrogen receptor (ER), progesterone receptor (PR), p53 and human epidermal growth factor receptor-2 (Her-2). RESULTS: There was no significant difference in the mean age for G3 EEC (n=68) and USPC+CC (n=38), (68.01 and 67.08 respectively, p=0.697) or stage at diagnosis (p=0.384). For ER, PR, p53 and Her-2, there was no significant difference in marker positivity between G3 EEC and UPSC+CC (p=0.612, 0.132, 0.16 and 0.132 respectively). With a mean follow-up time 148months Disease specific and recurrence-free survival between G3 EEC and USPC+CC was similar (p=0.842 and 0.863). CONCLUSION: G3 EEC and UPSC+CC share similar clinical, immunohistochemistry and poor survival. G3 EEC is better characterised as type 2 cancer and should be treated with similar adjuvant therapy to UPSC/CC.

Original language	English
Pages (from-to)	15-20
Journal	Gynecologic oncology
Volume	124
Issue number	1
DOIs	https://doi.org/10.1016/j.ygyno.2011.07.030
Publication status	Published - 22 Aug 2011

Bibliographical note

This paper was the first to demonstrate the continuum between grade 3 endometrioid cancer and uterine serous cancer – which are treated very differently. This concept has since been confirmed by Tumour cancer genomics analysis work on uterine cancer ( Nature May 2013) and highlighted in JCO Jan2014 in the article Clinical Cancer Advances 2013: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology. Citations 41

Keywords

grade 3
endometrioid carcinoma
type 2 cancer

ASJC Scopus subject areas

Oncology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.ygyno.2011.07.030

Cite this

@article{778588bfdfcd4441aa33d2a4de6bb1c3,

title = "Should grade 3 endometrioid endometrial carcinoma be considered a type 2 cancer-A clinical and pathological evaluation.",

abstract = "OBJECTIVE: Endometrial cancer is classified into: Type I estrogen-dependent endometrioid adenocarcinoma, with good prognosis and type 2 non-estrogen-dependent cancer with serous or clear cell histology and poor prognosis. Grade 3 endometrioid cancers (G3 EEC), share features of type 1 and type 2 cancer and have not been classified as either. This study compares immunohistochemistry and survival in G3 EEC and type 2 cancers. METHODS: Clinicopathological data compared with immunohistochemistry and survival in 156 consecutive patients with poor prognosis cancer-G3 EEC, uterine papillary serous (UPSC) and clear cell carcinoma (CC), sarcoma, carcinosarcoma and endometrial tumors of mixed histology. 131 (84%) datasets were complete, 25 tumors comprising sarcoma, carcinosarcoma or mixed histologies were excluded. Tissue microarray constructed and tested for estrogen receptor (ER), progesterone receptor (PR), p53 and human epidermal growth factor receptor-2 (Her-2). RESULTS: There was no significant difference in the mean age for G3 EEC (n=68) and USPC+CC (n=38), (68.01 and 67.08 respectively, p=0.697) or stage at diagnosis (p=0.384). For ER, PR, p53 and Her-2, there was no significant difference in marker positivity between G3 EEC and UPSC+CC (p=0.612, 0.132, 0.16 and 0.132 respectively). With a mean follow-up time 148months Disease specific and recurrence-free survival between G3 EEC and USPC+CC was similar (p=0.842 and 0.863). CONCLUSION: G3 EEC and UPSC+CC share similar clinical, immunohistochemistry and poor survival. G3 EEC is better characterised as type 2 cancer and should be treated with similar adjuvant therapy to UPSC/CC.",

keywords = "grade 3, endometrioid carcinoma, type 2 cancer",

author = "Martin Voss and Raji Ganesan and L Ludeman and K McCarthy and R Gornall and G Schaller and Wenbin Wei and Sudha Sundar",

note = "This paper was the first to demonstrate the continuum between grade 3 endometrioid cancer and uterine serous cancer – which are treated very differently. This concept has since been confirmed by Tumour cancer genomics analysis work on uterine cancer ( Nature May 2013) and highlighted in JCO Jan2014 in the article Clinical Cancer Advances 2013: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology. Citations 41 ",

year = "2011",

month = aug,

day = "22",

doi = "10.1016/j.ygyno.2011.07.030",

language = "English",

volume = "124",

pages = "15--20",

journal = "Gynecologic oncology",

issn = "1095-6859",

publisher = "Elsevier",

number = "1",

}

TY - JOUR

T1 - Should grade 3 endometrioid endometrial carcinoma be considered a type 2 cancer-A clinical and pathological evaluation.

AU - Voss, Martin

AU - Ganesan, Raji

AU - Ludeman, L

AU - McCarthy, K

AU - Gornall, R

AU - Schaller, G

AU - Wei, Wenbin

AU - Sundar, Sudha

N1 - This paper was the first to demonstrate the continuum between grade 3 endometrioid cancer and uterine serous cancer – which are treated very differently. This concept has since been confirmed by Tumour cancer genomics analysis work on uterine cancer ( Nature May 2013) and highlighted in JCO Jan2014 in the article Clinical Cancer Advances 2013: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology. Citations 41

PY - 2011/8/22

Y1 - 2011/8/22

N2 - OBJECTIVE: Endometrial cancer is classified into: Type I estrogen-dependent endometrioid adenocarcinoma, with good prognosis and type 2 non-estrogen-dependent cancer with serous or clear cell histology and poor prognosis. Grade 3 endometrioid cancers (G3 EEC), share features of type 1 and type 2 cancer and have not been classified as either. This study compares immunohistochemistry and survival in G3 EEC and type 2 cancers. METHODS: Clinicopathological data compared with immunohistochemistry and survival in 156 consecutive patients with poor prognosis cancer-G3 EEC, uterine papillary serous (UPSC) and clear cell carcinoma (CC), sarcoma, carcinosarcoma and endometrial tumors of mixed histology. 131 (84%) datasets were complete, 25 tumors comprising sarcoma, carcinosarcoma or mixed histologies were excluded. Tissue microarray constructed and tested for estrogen receptor (ER), progesterone receptor (PR), p53 and human epidermal growth factor receptor-2 (Her-2). RESULTS: There was no significant difference in the mean age for G3 EEC (n=68) and USPC+CC (n=38), (68.01 and 67.08 respectively, p=0.697) or stage at diagnosis (p=0.384). For ER, PR, p53 and Her-2, there was no significant difference in marker positivity between G3 EEC and UPSC+CC (p=0.612, 0.132, 0.16 and 0.132 respectively). With a mean follow-up time 148months Disease specific and recurrence-free survival between G3 EEC and USPC+CC was similar (p=0.842 and 0.863). CONCLUSION: G3 EEC and UPSC+CC share similar clinical, immunohistochemistry and poor survival. G3 EEC is better characterised as type 2 cancer and should be treated with similar adjuvant therapy to UPSC/CC.

AB - OBJECTIVE: Endometrial cancer is classified into: Type I estrogen-dependent endometrioid adenocarcinoma, with good prognosis and type 2 non-estrogen-dependent cancer with serous or clear cell histology and poor prognosis. Grade 3 endometrioid cancers (G3 EEC), share features of type 1 and type 2 cancer and have not been classified as either. This study compares immunohistochemistry and survival in G3 EEC and type 2 cancers. METHODS: Clinicopathological data compared with immunohistochemistry and survival in 156 consecutive patients with poor prognosis cancer-G3 EEC, uterine papillary serous (UPSC) and clear cell carcinoma (CC), sarcoma, carcinosarcoma and endometrial tumors of mixed histology. 131 (84%) datasets were complete, 25 tumors comprising sarcoma, carcinosarcoma or mixed histologies were excluded. Tissue microarray constructed and tested for estrogen receptor (ER), progesterone receptor (PR), p53 and human epidermal growth factor receptor-2 (Her-2). RESULTS: There was no significant difference in the mean age for G3 EEC (n=68) and USPC+CC (n=38), (68.01 and 67.08 respectively, p=0.697) or stage at diagnosis (p=0.384). For ER, PR, p53 and Her-2, there was no significant difference in marker positivity between G3 EEC and UPSC+CC (p=0.612, 0.132, 0.16 and 0.132 respectively). With a mean follow-up time 148months Disease specific and recurrence-free survival between G3 EEC and USPC+CC was similar (p=0.842 and 0.863). CONCLUSION: G3 EEC and UPSC+CC share similar clinical, immunohistochemistry and poor survival. G3 EEC is better characterised as type 2 cancer and should be treated with similar adjuvant therapy to UPSC/CC.

KW - grade 3

KW - endometrioid carcinoma

KW - type 2 cancer

U2 - 10.1016/j.ygyno.2011.07.030

DO - 10.1016/j.ygyno.2011.07.030

M3 - Article

C2 - 21864888

SN - 1095-6859

VL - 124

SP - 15

EP - 20

JO - Gynecologic oncology

JF - Gynecologic oncology

IS - 1

ER -

Should grade 3 endometrioid endometrial carcinoma be considered a type 2 cancer-A clinical and pathological evaluation.

Abstract

Bibliographical note

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Fingerprint

Cite this